Viridian Therapeutics, Inc.\DE (NASDAQ: VRDN)

Viridian Therapeutics Inc is a biopharmaceutical company focused on discovering developing and commercializing potential best-in-class medicines for serious and rare diseases The company targets therapeutic areas where current treatments leave room for improvements in efficacy safety and dosing convenience Viridian Therapeutics Inc develops product candidates directed at the insulin-like growth factor 1 receptor for thyroid eye disease inhibitors of the neonatal Fc receptor with potential application across multiple autoimmune disorders and a TSHR inhibitor program with potential in thyroid eye disease and Graves disease The company develops therapeutics through internal research and discovery as well as in-licensing opportunities that align with its strategic focus

Viridian Therapeutics Inc generates revenue through the development and anticipated commercialization of its product candidates The company's primary products in development include veligrotug and elegrobart for the treatment of thyroid eye disease VRDN-006 and VRDN-008 for autoimmune disorders and a TSHR inhibitor candidate for Graves disease and thyroid eye disease Revenue generation is expected from product sales following regulatory approval and commercial launch with current efforts focused on clinical development and regulatory submissions

The company operates through the following segments: TED IGF-1R Therapies FcRn Inhibitors TSHR Inhibitors

• TED IGF-1R Therapies segment includes veligrotug an intravenously administered monoclonal antibody and elegrobart a subcutaneously administered monoclonal antibody both targeting the IGF-1R pathway for the treatment of active and chronic thyroid eye disease Veligrotug is in phase 3 clinical development with a BLA submitted to the FDA and Priority Review granted elegrobart is in pivotal phase 3 clinical studies with topline data anticipated in 2026.

• FcRn Inhibitors segment includes VRDN-006 a highly selective Fc fragment and VRDN-008 a half-life extended bispecific FcRn inhibitor both designed for subcutaneous self-administration to treat autoimmune diseases by inhibiting IgG levels while sparing albumin and LDL VRDN-006 has completed phase 1 clinical trials in healthy volunteers and VRDN-008 has received IND clearance with healthy volunteer data expected in the second half of 2026.

• TSHR Inhibitors segment includes a half-life extended monoclonal antibody designed to inhibit activation of the TSHR for potential use in Graves disease and thyroid eye disease The product candidate is being developed for subcutaneous administration via autoinjector with an IND submission anticipated in the fourth quarter of 2026.

Viridian Therapeutics Inc operates in the competitive biopharmaceutical industry focused on autoimmune and rare diseases The company faces competition from established players such as Amgen with Tepezza for thyroid eye disease and Argenx with Vyvgart for FcRn inhibition Viridian Therapeutics Inc differentiates itself through its focus on potential best-in-class product candidates with improved dosing convenience safety profiles and mechanisms of action such as full IGF-1R antagonism and extended half-life engineering

Viridian Therapeutics Inc serves patients with serious and rare diseases including those with thyroid eye disease Graves disease and various autoimmune disorders The company's customer base includes individuals seeking treatment for chronic and active thyroid eye disease patients with myasthenia gravis chronic inflammatory demyelinating polyneuropathy and other autoimmune conditions targeted by its FcRn inhibitor portfolio and individuals affected by Graves disease